-Economic and Political Weekly Ten years on, the progressive provisions of the amended Indian Patents Act are being watered down. Ten years have passed since the Indian Patents Act, 1970 was amended in 2005 to bring the country’s laws in line with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most important of the 2005 amendments was the introduction of product patents for 20 years, including for pharmaceutical products,...

-The Telegraph Guwahati: A survey on women drug users in the Northeast has found that a majority of them were unaware of the perils of sharing needles to inject drugs. The study was commissioned by the United Nations Office on Drugs and Crime (UNODC) under its regional initiative. Termed Prevention of Transmission of HIV Amongst Drug Users in SAARC Countries, the initiative was in response to the gap of knowledge regarding women...

-The Hindu Business Line Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on Hepatitis C drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month. Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application...

-The Times of India NEW DELHI: The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them in India. The move, a first of its kind, is also likely to be applied on patented drugs that are already being sold in the country, an official source said. An inter-ministerial committee, evaluating the mechanism to negotiate prices of patented medicines, has recently sought detailed information about...

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat Hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900...